STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity

The preprint operates within the dominant paradigm of cancer immunology, specifically focusing on the role of dendritic cells (DCs) in mediating anti-tumor immunity, particularly in the context of immune checkpoint blockade (ICB) therapy. It explores the interplay between STAT3 and STAT5 signaling pathways in DCs and their impact on ICB efficacy.

This preprint represents normal science as it investigates specific molecular mechanisms within the established paradigm of cancer immunology. The study delves into the intricacies of DC function and their interaction with ICB, building upon the existing knowledge base and refining our understanding of how these components contribute to anti-tumor immunity. It does not propose a radical shift in understanding or challenge the fundamental tenets of the field, instead focusing on detailed exploration within the accepted framework. While the development of STAT3 degraders as potential therapeutic agents could be considered a novel approach, the study primarily focuses on understanding the underlying biological mechanisms, which aligns with the goals of normal science. Therefore, the classification of 'Normal Science' accurately reflects the preprint's contribution to the field.